Abstract
MicroRNA Expression Changes in Parkinson’s Disease (PD) Patients’ Leukocytes Prior to and Following Deep Brain Stimulation (DBS)
Lilach Soreq*
Corresponding Author: Lilach Soreq, UCL, Israel.
Revised: December 17, 2021; Available Online: December 17, 2021
Citation: Soreq L. (2021) MicroRNA Expression Changes in Parkinson’s Disease (PD) Patients’ Leukocytes Prior to and Following Deep Brain Stimulation (DBS). J Psychiatry Psychol Res, 5(S1): 04.
Copyrights: ©2021 Soreq L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 509

    Views & Citations
  • 10

    Likes & Shares
The second most prevalent neurodegenerative disorder worldwide in the elderly is Parkinson's disease (PD). It is a major risk factor for aging.

Objectives: Currently the involvement of miRNAs in the disease is mainly unclear. Additionally, the disease etiology is complex and there are no available disease-modifying medications. Therefore, more evidence is required concerning its pathogenesis and developing new treatment modalities.

Methods: Here, we studied the expression profiles of about 900 miRNAs in PD patients prior to and following deep brain stimulation (DBS) both on and following 1 hour off electrical stimulation and as compared with age and gender matched healthy control (HC) donor samples, using Affymetrix miRNA microarrays. We analyzed statistically the data using Affymetrix expression console software.

Results: We detected significantly altered miRNAs pre and post DBS treatment.

Conclusions: Our findings indicate the involvement of miRNAs in PD. Future studies can enlarge the number of samples and use RNA sequencing platform to quantify further miRNAs in PD samples. We may also use the expression levels of miRNAs as biomarkers for PD in the blood.

Keywords: PD, RNA, DBS, Microarray, Blood, Leukocytes